Author: Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer On April 18, 2024, the U.S. Food and Drug Administration (FDA) approved Alecensa (alectinib) following surgical resection for people living with early-stage ALK-positive non-small cell lung [...]
Craig S. lives in Washington, D.C., with his wife, Lydia, and daughter, Lola, who is a freshman at Tulane University. He has worked in software sales and sales leadership since getting his MBA from George [...]
By Shelly Engfer-Triebenbach I was just finishing up my 18th year of teaching music when I noticed myself getting short of breath doing easy things. I went to see my primary care doctor who gave me antibiotics and [...]
First and Only Global Lung Cancer Registry Through its Lung Cancer Registry, GO2 for Lung Cancer securely gathers information from lung cancer patients across the globe - providing researchers with rich data from which to identify trends that can [...]
Sydney Barned, MD, was 33 years old and in her medical residency when she was diagnosed with stage 4 ALK-positive lung cancer. A year prior to diagnosis, she woke up with severe shortness of breath and decided she needed [...]
Amanda Nerstad, SPACEWALK participant, with family By Daniel A. Saez, MSc, Treatment and Trials Navigator, GO2 for Lung Cancer One of the biggest concerns within the mutation positive non-small cell lung cancer (NSCLC) community is the concept [...]
Usha Jain (left) and daughter, Amita Jain (right) Lung cancer doesn’t just impact one person—it affects all those who love them. Perhaps no family understands this better than the Jain-Patkar family. Meet Usha Jain, a [...]
Addario Lung Cancer Medical Institute and GO2 for Lung Cancer to learn about environmental, lifestyle, and demographic risks of developing lung cancer under the age of 40 San Carlos, CA/Washington DC – Continuing their collaboration to transform lung cancer [...]
Australian Lisa Briggs is proof that living on a different continent is no impediment to connecting with GO2 for Lung Cancer. In 2014, after months of misdiagnosis, she learned she had stage IV lung cancer, ALK-positive. The 32-year-old healthcare [...]
On May 22, 2020, the Food and Drug Administration (FDA) approved Alunbrig (brigatinib) for the first line treatment of advanced non-small cell lung cancer (NSCLC) with tumors having changes in ALK. The FDA based their approval on the results [...]